The EIF2D Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population derived from the HeLa human cervical carcinoma cell line, designed to create a loss-of-function model for the EIF2D gene. This product comprises a heterogeneous mixture of cells harboring targeted disruptions in the EIF2D locus, collectively abolishing functional EIF2D protein expression. The CRISPR/Cas9-mediated gene disruption strategy yields a versatile pool suitable for studying the genetic requirements of cap-independent translation and stress-responsive protein synthesis. As a polyclonal knockout product, it avoids clonal artifacts and enables robust functional genomic screening within a diverse isogenic background.
HeLa cells are an immortalized epithelial line originally isolated from a cervical adenocarcinoma, characterized by aneuploidy and the presence of integrated human papillomavirus type 18 (HPV18) sequences. The viral oncoproteins E6 and E7 disrupt the p53 and retinoblastoma tumor suppressor pathways, respectively, driving rapid proliferation, genomic instability, and resistance to apoptosis. These features make HeLa cells a widely adopted model for investigating oncogenic signaling, viral carcinogenesis, and the interplay between translational control and cellular transformation.
EIF2D functions as a non-canonical translation initiation factor that promotes ribosome recruitment to mRNAs containing internal ribosome entry sites (IRES) and enhances reinitiation on transcripts with upstream open reading frames. Its activity is particularly crucial under stress conditions when cap-dependent translation is globally suppressed through phosphorylation of eIF2?? by kinases such as GCN2 and PERK. EIF2D operates downstream of mTORC1 signaling; upon mTORC1 inhibition by stimuli like ER stress or amino acid deprivation, the transcription factor ATF4 is induced, and EIF2D facilitates the translation of select downstream targets including the oncogenes c-MYC, VEGF, and XIAP. EIF2D physically interacts with the eIF3 complex, ribosomal subunits, and poly(A)-binding protein, positioning it at a key intersection of stress sensing and selective mRNA translation.
In the HeLa cervical carcinoma background, where constitutive mTORC1 activation and HPV-driven perturbations create a unique translational landscape, EIF2D knockout is expected to impair the expression of IRES-dependent oncogenic factors and stress-adaptive proteins. This polyclonal knockout model permits dissection of how cap-independent translation contributes to the transformed phenotype and how cells rewire translation in response to nutrient deprivation or other stresses. By providing a relevant epithelial tumor context, the cells enable functional interrogation of EIF2D-dependent mechanisms underlying proliferation, survival, and therapeutic vulnerabilities.
Researchers can utilize EIF2D Knockout HeLa Polyclonal Cells in diverse experimental setups, including Western blotting to verify EIF2D loss and monitor c-MYC or VEGF levels, dual-luciferase IRES reporter assays to measure cap-independent initiation activity, and polysome profiling combined with RNA-seq to capture genome-wide translational changes. Cell proliferation assays, flow cytometry for apoptosis under stress conditions, and chemical screens for IRES-targeting inhibitors are also highly applicable. This product serves as a valuable tool for elucidating non-canonical translation pathways and their roles in cancer biology. For further information or to discuss specific experimental applications, please contact Ascent Research.
